The test of the lowest price of the new basic medicine is coming! The market of 280 drugs will shrink obviously next year!

Medical network, Nov 20 Hubei officially issued the notice on the implementation of national essential drugs catalogue (2018 Edition) on Nov 19 According to the notice, for the drugs that are not base drugs and are newly listed in the 2018 version of the base drug catalog, the online price shall be adjusted to the lowest price in China At the same time, as of the end of this year, the original 280 kinds of basic drugs supplemented by the province and not included in the new version of the basic drug catalogue will continue to be managed according to the basic drug, and the catalogue will be abolished at the beginning of next year, and will be changed to "non base drug" management According to the requirements of Hubei Province, the price of new basic drugs should be the lowest in the country For the drugs in the new version of the list of drugs on the Internet of public hospitals in Hubei Province, which are classified as "non basic drugs", the price on the Internet should be adjusted to be the lowest in the country in the same enterprise and the same product specification After the enterprise confirms, the drug attribution should be changed to "basic drugs" and included in the basic drug management Up to now, most of the provinces and cities in the country have released the relevant landing measures for new base drugs, and it is expected that the remaining provinces and cities will continue to issue policies in the near future For the consideration of price, all regions continue the previous requirements This time, Hubei made it clear that the price should be the lowest in the country, which also released an attitude After all, the basic medicine is mainly to guarantee the basic clinical drug demand, and the price is generally not too expensive But this new version of the catalogue includes 12 kinds of anti-tumor drugs, new drugs for hepatitis C treatment, etc., and the price really needs to be reconsidered Compared with Hubei, some regions have slightly loose price requirements On November 16, Gansu Province issued the notice on matters related to the newly added Sunshine Network of national essential drugs catalogue 2018, which clearly stated that "for drugs included in the newly added sunshine network directory of essential drugs, green channels shall be opened and zero filing application shall be implemented All declared drugs shall promise that the actual supply price of medical institutions in Gansu Province shall not be higher than the national average supply price " Price decline is the general trend, especially under the price linkage, the prices of different regions gradually converge In the view of the industry, the sales of basic drugs are mainly at the grass-roots level Now, the control of fees at the grass-roots level is becoming more and more strict, and the high-priced drugs can no longer be sold In addition, there are many similar products in the base drug, and the use amount should not be large In the past, enterprises thought that high bidding price is a good thing, but in the future it may not be For example, after hospitals implement single disease and pay by disease, products with high price are no longer popular, so now enterprises are also thinking about what kind of price is more appropriate Although the price requirement is the lowest, Hubei also put forward supporting policies for the use of base drugs Hubei requires all public medical institutions to adjust their drug use catalogue in time according to the functional orientation and scope of diagnosis and treatment, in accordance with the new version of the catalogue, so as to ensure the priority of national essential drugs At the same time, we should improve the information system of medical institutions, mark the essential drugs, strengthen the training of doctors, pharmacists and managers on the clinical application of essential drugs, prescription set, and improve the level of rational use and management of essential drugs And give full play to the role of pharmacists, regard the use of basic drugs as an important content of prescription review, and regularly make statistical analysis and report At present, all over the country have released different degrees of advantages to the basic drug system Tianjin will give encouragement and support in the medical insurance end When adjusting the medical insurance drug catalog, for the therapeutic drugs in the basic drug catalog, the qualified basic drugs will be included in the catalog preferentially according to the procedures Liaoning proposes that the national essential drugs will not be included in the calculation of the proportion of drugs in public hospitals Losing the identity of drug base for sale is worth noting that price is only a factor for the effective implementation of drug base system, and enterprises are more concerned about the amount of use In this regard, Hubei requires that the implementation of the basic drug system of medical institutions in the jurisdiction be included in the local government performance appraisal system according to the requirements of the current proportion of basic drug allocation and use to ensure effective results According to the use of the new version of the local directory, the health commission of Hubei Province will separately formulate the proportion of basic drugs used by public medical institutions in the province every year, and link the use with the allocation of basic drug subsidies Another thing to be noted is that Hubei has decided to implement the "transition period" for the province's essential drug catalogue from the date of issuance to December 31, 2018, and implement the relevant policies of the "transition period" During the transitional period, 280 kinds of non catalogue drugs at the provincial level continued to be managed according to the basic drugs After the transitional period, the catalogue of non catalogue drugs at the provincial level was abolished and changed to "non base drugs" management Under the principle that the new version of the catalogue is no longer supplemented by the provinces as required by the state, the varieties added by the original provinces and not included in the new version of the catalogue will gradually lose their "identity" as base drugs in each province Shandong proposed that "the original province supplemented the basic drugs, and no longer retained the basic drug properties." Chongqing also said that "the original 2013 Chongqing supplementary drug list will be abolished." Not long ago, Qinghai provincial health and Family Planning Commission requested in the notice on Soliciting Opinions on data adjustment of procurement platform of national essential drug catalog (2018 Edition) that the original supplementary catalog of basic drugs in Qinghai should change the attribute of varieties of drugs not included in 2018 edition of basic drug catalog to "non basic drugs" According to the information released by the platform, irbesartan (dispersible tablets, capsules, tablets: 75mg, 150mg), dextromethorphan (solution: 10ml: 15mg; granules: 15mg), compound reserpine aminopteridine (tablets), metformin (capsules, 0.5g), loratadine (tablets, 5mg) and other varieties were changed to non essential drugs After the implementation of the new catalogue, the prospects of basic and non basic drugs in the primary market may be different In particular, the varieties that originally entered the provincial supplement but did not enter the new base drug catalogue will face an awkward situation at the grass-roots level According to rough statistics, after the publication of the 2012 520 base drug catalog, the number of supplements in each province is different, with an average number of about 200 kinds In response, business people said that many enterprises will be affected Because the market operation mode of base drug is quite different from OTC and grade hospital market, the base drug market is more dependent on policy With the identity of basic medicine, and then do academic and promotion, sales will naturally rise However, when the power of the policy weakens, these varieties will be transferred to the market, such as OTC terminals, which will put forward new requirements for marketing mode, team and personnel Generally speaking, it is difficult to transform base drugs and OTC, so sales will still have a great impact.